Cell Death Research & Therapy (CDRT) Unit, Department of Cellular and Molecular Medicine, KU Leuven University of Leuven, Belgium.
Melanoma Laboratory, Molecular Oncology Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
FEBS J. 2016 Jan;283(1):25-38. doi: 10.1111/febs.13545. Epub 2015 Oct 29.
A common feature of solid tumors is their ability to incite the formation of new blood and lymph vessels trough the processes of angiogenesis and lymphangiogenesis, respectively, to support tumor growth and favor metastatic dissemination. As a result of the lack of feedback regulatory control mechanisms or due to the exacerbated presence of pro-angiogenic signals within the tumor microenvironment, the tumor endothelium receives continuous signals to sprout and develop, generating vessels that are structurally and functionally abnormal. An emerging mechanism playing a central role in shaping the tumor vasculature is the endothelial-vesicular network that regulates trafficking/export and degradation of key signaling proteins and membrane receptors, including the vascular endothelial growth-factor receptor-2/3 and members of the Notch pathway. Here we will discuss recent evidence highlighting how vesicular trafficking mechanisms in endothelial cells contribute to pathological angiogenesis/lymphangiogenesis and can provide novel and exploitable targets in antiangiogenic therapies.
实体瘤的一个共同特征是它们分别通过血管生成和淋巴管生成过程来激发新的血液和淋巴管的形成,以支持肿瘤生长并有利于转移扩散。由于缺乏反馈调节控制机制,或者由于肿瘤微环境中促血管生成信号的加剧,肿瘤内皮细胞不断接收到发芽和发育的信号,生成结构和功能异常的血管。一种在塑造肿瘤血管系统中起核心作用的新兴机制是内皮小泡网络,它调节关键信号蛋白和膜受体(包括血管内皮生长因子受体-2/3 和 Notch 途径成员)的运输/输出和降解。在这里,我们将讨论最近的证据,强调内皮细胞中的小泡运输机制如何促进病理性血管生成/淋巴管生成,并为抗血管生成治疗提供新的和可利用的靶点。